June 17, 2022
1 min learn
Final week, Healio supplied stay protection of Digestive Illness Week, the biggest gathering of consultants in gastroenterology, hepatology, endoscopy and gastrointestinal surgical procedure.
Throughout one presentation, researchers reported {that a} rectal expulsion gadget could assist predict whether or not sufferers with persistent constipation will expertise enhancements with pelvic ground bodily remedy. It was the highest story in gastroenterology final week.
The second high story coated a debate at Digestive Illness Week on the optimum technique for liver biopsy: percutaneous vs. endoscopic ultrasound.
Learn these and extra high tales in gastroenterology under:
Rectal expulsion gadget could predict outcomes in sufferers with persistent constipation
An investigational, point-of-care rectal expulsion gadget could assist decide whether or not sufferers with persistent constipation will enhance with pelvic ground bodily remedy, in response to knowledge offered at Digestive Illness Week 2022. Read more.
Debate: ‘Security, adequacy, value’ nonetheless favor percutaneous vs. endoscopic ultrasound biopsy
Though percutaneous liver biopsy continues to be the “gold customary,” advances in strategies and elevated use of endoscopic ultrasound-guided biopsy could quickly change that dynamic, in response to a debate. Read more.
Extra doses of SARS-CoV-2 vaccine heighten antibody response in sufferers with IBD
Seroconversion charges and antibody response considerably elevated after a 3rd dose of SARS-CoV-2 vaccine in sufferers with inflammatory bowel illness, in response to a presenter. Read more.
VIDEO: Oral S1P receptor modulator induces medical remission in UC
In a Healio video unique, Marla C. Dubinsky, MD, discusses outcomes from the ELEVATE UC trials, during which as soon as every day etrasimod induced medical remission in sufferers with ulcerative colitis. Read more.
VIDEO: Mirikizumab induces, maintains medical remission at 1 yr in UC sufferers
Sufferers with ulcerative colitis who responded to mirikizumab at 12 weeks achieved and maintained medical remission and improved bowel urgency severity at 1 yr within the section 3 LUCENT-2 research. Read more.
